

Limited Review Report

**The Board of Directors
TAKE Solutions Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results (the statement) of TAKE Solutions Limited for the quarter ended June 30, 2020. This statement which is the responsibility of the Company's Management has been approved by the Board of Directors. The statement has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We draw attention to the following matter in the Notes to the standalone financial results:

The management has taken into consideration the impact of the known internal and external events arising from COVID-19 pandemic in the assessment of recoverability of trade receivables, contract assets and certain investments in subsidiaries up to the date of approval of these financial results. In this assessment, the company has performed sensitivity analysis on the key assumptions used. Such review and analysis performed by the company did not reveal any impairment losses. However, the liquidity and business constraints consequent to impact of COVID 19 pandemic has significantly hampered the operations of a step-down subsidiary viz. Navitas Life Sciences GmbH, Germany (a subsidiary of Ecron Acunova Limited, which is a subsidiary of TAKE Solutions Limited) and the liquidation process has been initiated as per the requirements of local laws. While such liquidation proceedings are in progress, the loss of Rs. 15,662.33 lakhs to the extent of net assets has been accounted for in Consolidated Financial Statements. Considering the business projections, no impairment is required to be made against investments of the company in Ecron Acunova Limited in the Standalone Financial Results.



G. D. Apte & Co.
Chartered Accountants

Since the impact assessment of COVID-19 is an ongoing process given the uncertainties associated with its nature and duration, the Company will continue to closely monitor any significant impact on the financial position. The impact of global health pandemic might be different from that estimated as at the date of approval of these financial results.

Our conclusion is not modified in respect of the above matter.

For G. D. Apte & Co.
Chartered Accountants
Firm Registration Number: 100515W
UDIN: 20113053AAAADH3492



Umesh S. Abhyankar
Partner
Membership Number: 113 053
Pune, September 14, 2020





TAKE SOLUTIONS LTD

CIN: L63090TN2000PLC046338

Regd. Office : 27, Tank Bund Road, Nungambakkam, Chennai 600 034

www.takesolutions.com

Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2020

(₹ In Lakhs except per share data)

Sl. No.	Particulars	Quarter Ended			Year Ended
		Jun 30, 2020	Mar 31, 2020	Jun 30, 2019	Mar 31, 2020
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	1.73	63.02	48.46	246.55
2	Other Income	433.53	1,601.89	590.29	4,464.59
3	Total Income	435.26	1,664.91	638.75	4,711.14
4	Expenses				
	Cost of revenue	1.59	60.30	21.80	178.44
	Employee benefit expenses	122.93	148.53	186.00	632.24
	Finance cost	9.49	9.86	11.30	42.51
	Depreciation and amortisation	39.24	39.28	45.52	174.17
	Other expenses	192.40	139.64	226.10	1,133.13
	Total Expenses	365.65	397.61	490.72	2,160.49
5	Profit/(Loss) before tax (3-4)	69.61	1,267.30	148.03	2,550.65
6	Tax expense				
	Current tax	12.34	171.60	22.68	197.71
	Shortfall / (excess) provision of earlier years	-	-	-	(86.63)
	Deferred tax	(41.96)	28.12	(32.84)	(54.25)
7	Profit/(Loss) for the period (5-6)	99.23	1,067.58	158.19	2,493.82
8	Other Comprehensive Income				
	a) i) Items that will not be reclassified to profit or (loss)	(0.92)	2.03	(1.08)	(1.30)
	ii) Income tax provision / (reversal) relating to the items that will not be reclassified to profit or (loss)	(0.23)	0.58	(0.31)	(0.33)
	b) i) Items that will be reclassified to profit or (loss)	-	-	-	-
	ii) Income tax provision/(reversal) relating to the items that will be reclassified to profit or (loss)	-	-	-	-
	Total Other Comprehensive Income	(0.69)	1.45	(0.77)	(0.97)
9	Total Comprehensive Income	98.54	1,069.03	157.42	2,492.85
10	Paid-up equity share capital (Face value ₹ 1/- each)	1,479.34	1,479.34	1,479.34	1,479.34
11	Earnings per share (of ₹ 1/- each) (not annualised)				
	(a) Basic (in ₹)	0.07	0.72	0.11	1.69
	(b) Diluted (in ₹)	0.07	0.71	0.11	1.68

Note:

- The Standalone Financial Results for the quarter ended June 30, 2020 have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the company in their respective meetings held on September 14, 2020. The Statutory Auditors of the company have carried out Limited Review of the results for the quarter ended June 30, 2020.
- The company on a standalone basis operates in the business segment of promotion of services related to Life Sciences and hence there is only one business segment. The company on a standalone basis is primarily operating in India, which is considered as single geographical segment. Accordingly, segment information has not been separately disclosed.
- The management has taken into consideration the impact of the known internal and external events arising from COVID-19 pandemic in the assessment of recoverability of trade receivables, contract assets and certain investments in subsidiaries up to the date of approval of these financial results. In this assessment, the company has performed sensitivity analysis on the key assumptions used. Such review and analysis performed by the company did not reveal any impairment losses. However, the liquidity and business constraints consequent to impact of COVID 19 pandemic has significantly hampered the operations of a step-down subsidiary viz. Navitas Life Sciences GmbH, Germany (a subsidiary of Ecron Acunova Limited, which is a subsidiary of TAKE Solutions Limited) and the liquidation process has been initiated as per the requirements of local laws. While such liquidation proceedings are in progress, the loss of ₹15,662.33 lakhs to the extent of net assets has been accounted for in Consolidated Financial Statements. Considering the business projections, no impairment is required to be made against investments of the company in Ecron Acunova Limited in the Standalone Financial Results.

Since the impact assessment of COVID-19 is an ongoing process given the uncertainties associated with its nature and duration, the Company will continue to closely monitor any significant impact on the financial position. The impact of global health pandemic might be different from that estimated as at the date of approval of these financial results.
- During the quarter ended June 30, 2020, employees have not exercised any equity shares under Employee Stock Option Scheme of the Company.
- Previous period figures have been regrouped /reclassified, wherever necessary to conform to current period's classification.

Place : Chennai
Date : September 14, 2020



For and on behalf of the Board of Directors

Srinivasan H.R.

Srinivasan H.R.
Vice Chairman & Managing Director